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Abstract
Background-5-Lipoxygenase products
play a part in inflammatory response.
Aims-The effect of intracolonic admini-
stration of zileuton (a 5-lipoxygenase
inhibitor) on colonic damage and
eicosanoid local release was assessed in a
rat model of colitis.
Methods-Ninety rats with trinitroben-
zenesulphonic acid induced colitis were
randomised to receive placebo, 5-amino-
salicylic acid (50 mglkg), or zileuton
(50 mg/kg) intracolonically for four weeks.
Local eicosanoid release was monitored
by intracolonic dialysis throughout the
study. The colon was removed for macro-
scopic and histological assessment at
weeks 1, 2, and 4 after colitis induction in
10 rats of each group.
Results-Zileuton significantly reduced
macroscopic damage score after four
weeks oftreatment in comparison with the
other two groups (p=0.034). In addition,
zileuton administration significantly
increased the intracolonic release of both
thromboxane B2 at week 1 (p=0.05) and
prostaglandin E2 at weeks 2 and 4
(p<0.05). Zileuton and 5-aminosalicylic
acid decreased leukotriene B4 release by
900/0 at day 3.
Conclusions-Intracolonic zileuton, com-
pared with 5-aminosalicylic acid and
placebo,seems to improve the course of
the disease in a model of chronic colitis.
This effect may be related to an increased
and maintained production of prosta-
glandin E2 together with inhibition of
leukotriene B4 synthesis.
(Gut 1996; 38: 899-904)
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The aetiology of inflammatory bowel disease
(IBD) remains undefined, but it is recognised
that in both acute and chronic forms, inflam-
matory mediators are generated within the
colonic mucosa. Some of these mediators, the
eicosanoids (thromboxanes, prostaglandins,
and leukotrienes) are products of the metabo-
lism of arachidonic acid by the action of both
cyclooxygenase and 5-lipoxygenase.1
The role for lipoxygenase products of
arachidonic acid in the pathogenesis of IBD is
supported by the finding in experimental
models of colitis that the concentration of
leukotrienes (mainly leukotriene B4 (LTB4)) in
the inflamed mucosa is within the range known
to induce biological effects (chemokinesis, cell
aggregation, increasing of vascular permeabil-
ity), and these concentrations are similar to
those seen in human IBD.2-7 In addition,
drugs known to be effective in the treatment of
IBD are capable of reducing intestinal
leukotriene production in both experimental
models of colitis and human IBD.36 On the
other hand, administration ofpotent and selec-
tive inhibitors of leukotriene synthesis results
in a reduction of macroscopic and histological
colonic damage in experimental colitis.6 8-11
Zileuton, N-(1-(benzo[b]thien-2-yl)ethyl)-
N-hydroxyurea (Abbott Laboratories, Abbott
Park, IL), is a drug that selectively inhibits the
activity of 5-lipoxygenase. In humans, the oral
administration of a single dose of 800 mg
reduces the synthesis ofLTB4 measured in rec-
tal dialysates by approximately 67% within
four hours, with no significant toxicity.'2 In
recent double blind randomised trials, how-
ever, the use of zileuton at doses ranging from
800 mg twice daily to 600 mg four times a day,
either as treatment of active disease or for
maintenance of remission, in patients with
ulcerative colitis, have shown poor or marginal
results.'3 14 For this reason, the evaluation of
alternative routes of administration of zileuton,
such as intrarectal, may be of importance to
assess the possibility of improving the thera-
peutic effect of this drug.
The aim of this study was to assess the effect
of the intracolonic administration of zileuton,
compared with 5-aminosalicylic acid (5-ASA)
and placebo, on the macroscopic and histo-
logical damage and on the eicosanoid local
release in an experimental model of colitis in
rats.
Methods
Animals
Female virgin Sprague-Dawley rats weighing
200-250 g were used in this study. The
animals were maintained in a restricted access
room with controlled temperature (23°C) and
light/dark cycle (16 h:8 h). The rats were
housed in individual isolated rack mounted
wire cages. Standard laboratory pelleted
formula (Rat chow, Panlab, Barcelona, Spain)
and tap water were provided ad libitum. The
study was conducted, in agreement with the
guidelines for animal research, according to
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the Guide for the Care and Use of Laboratory
Animals, and was approved by the research
and ethical committee of our hospital.
Experimental colitis
Experimental colitis was induced using the
method described by Morris et al.15 In brief,
rats were lightly anaesthetised with ether and a
polyurethane catheter (OD 2 mm) was
inserted rectally into the colon so that the tip
was 8 cm proximal to the anus, approximately
at the splenic flexure. Then, 0.25 ml of a mix-
ture of 30 mg of trinitrobenzenesulphonic acid
(TNB) (Sigma-Aldrich Quimica, Madrid,
Spain) dissolved in 50°/o ethanol (vol/vol) was
instilled into the lumen of the colon. The
instillation procedure required five seconds to
complete. Finally, 0.5 ml of air was injected to
clear completely the TNB/ethanol solution
from the cannula, and the anaesthetised
animals were kept for a few minutes in a supine
Trendelenburg position.
Experimental design
TNB/ethanol colitis was induced in 90 rats.
Animals were thereafter randomised into three
therapeutic groups to receive daily, from day 1
(24 hours after induction of colitis):
Group A (n=30) - 0.25 ml of vehicle solution
enema (1-5% carboxymethylcellulose in saline
serum) (placebo group).
Group B (n=30) - 0.25 ml of the vehicle solu-
tion enema added with 50 mg/kg of body
weight of 5-ASA.
Group C (n=30) - 0-25 ml of the vehicle solu-
tion enema added with 50 mg/kg of body
weight of zileuton.
In addition, a sham colitis was induced, by
intrarectal administration (as described above)
of 0-25 ml of 0.9°/0 saline, in 10 rats (control
group).
At day 1 and 3, and at weeks 1, 2, and 4, 10
rats from groups A, B, and C were randomly
selected for the assessment of eicosanoid
release in the lumen of the colon by intra-
colonic dialysis. Rats were anaesthetised with
100 mg of intraperitoneal thiopental and intra-
colonic dialysis was performed using hydrated
Visking seamless cellulose tubing (8/32, 6-3
mm diameter, 7 cm long; Medicell
International, London) attached by a 10 cm
polyurethane cannula to an external syringe.
After inserting the entire cannula into the distal
colon, the dialysis bag was filled with 1 ml of
dialysis solution, consisting of 0.3°/o bovine
serum albumin in a solution of 120 mmol/l
NaCl and 30 mmol/l KHCO3 adjusted to pH
7.90. One hour later,5 the fluid was withdrawn
and immediately stored at -30C. The volume
of the dialysate recovered at the end of the one
hour period was higher than 90%. In the
control group (n= 10), an intracolonic dialysis
was performed in the same way 24 hours after
the sham colitis induction.
The day after the dialysis was performed at
weeks 1, 2, and 4, the same animals were given
a distal colectomy under total anaesthesia with
100 mg of intraperitoneal thiopental, to assess
TABLE I Macroscopic damage score
Adhesions
None 0
Minimal 1
Involving several bowel loops 2
Strictures
None 0
Mild 2
Severe; proximal dilatation 3
Ulcers
None 0
Linear ulceration < 1 cm 1
Two linear ulcers < 1 cm 2
More sites of ulceration or one large ulcer > 1 cm 3
Wall thickness
Less than 1 mm 0
1-3 mm 1
More than 3 mm 2
Maximum score 10
colonic inflammation macroscopically and
histologically. The excised colon was opened
longitudinally, rinsed with normal saline,
pinned out on a wax block, and assigned a code
number. Mucosal damage was assessed macro-
scopically as described later. Afterwards, three
tissue specimens (2X 10 mm) were obtained
from the colon. When no severely visible
inflammation was present, the specimens were
taken from the regions 1 cm, 3 cm, and 8 cm
proximal to the anus. When visible lesions were
present, the specimens were taken from the
affected regions. Tissue samples were fixed in
formaldehyde and routinely processed. In the
control group (n= 10) the rats were killed in the
same way 48 hours after induction of sham
colitis.
Assessment of colonic inflammation
The macroscopic assessment of colonic dam-
age was immediately made using a stereo-
microscope by two observers blinded to the
treatment. Each colon was assigned a score on
a scale ranging from 0 to 10 based on the
presence of adhesions, strictures, ulcers, and
wall thickness (Table I). 16
The samples taken to study the histological
damage were embedded in paraffin wax.
Sections (7,u) were stained with haematoxylin
and eosin. The histological damage was scored
on a scale ranging from 0 to 10 based on the
presence of ulceration, inflammation, granu-
TABLE II Histological damage score
Ulceration
No ulcer; epithelisation
Small ulcers <3 mm
Large ulcers >3 mm
Inflammation
None
Mild
Severe
Granuloma*
None
Presence
Depth of the lesion
None
Submucosa
Muscularis propria
Serosa
Fibrosis
None
Mild
Severe
Maximum score
*Epithelioid granuloma is defined using the criteria of
Surawicz and Belic41: collections of at least five epithelioid
cells, with or without accompanying giant cells, and without
caseation necrosis or foreign bodies.
0
1
2
0
1
2
0
1
0
1
2
3
0
1
2
10
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TABLE III Individual items and total score of macroscopic damage at first, second, andfourth weeks after administration
of TNB (30 mg/50%9o) in the three treatment groups. Each figure represents the mean (SEM) of at least seven rats
Placebo Zileuton 5-ASA
Weeks 1 2 4 1 2 4 1 2 4
Adhesions 1-5 (0.2) 1-6 (0.2) 1-7 (0.2) 1-3 (0.1) 1-6 (0.2) 1.1 (0.3) 1-3 (0.2) 1-7 (0.2) 1-4 (0.2)
Strictures 2-3 (0.3) 2-6 (0.2) 1-4 (0.4) 2-6 (0.2) 2-3 (0.4) 0-6 (0Q4)* 2-6 (0.2) 2-3 (0.3) 1-9 (0.3)
Ulcers 2-7 (0.1) 2-9 (0 1) 2-1 (0.3) 3.0 (0.0) 2-3 (0.5) 1-4 (0.3) 2-8 (0.1) 2-8 (0.1) 2 4 (0.3)
Wall thickness 1-5 (0.2) 1-4 (0.2) 0-8 (0.1) 1-2 (0.1) 1-6 (0.2) 0-8 (0.1) 1.8 (0 1) 1-3 (0.2) 1-2 (0.2)
Total score 8-0 (0.5) 8-5 (0.3) 6-1 (0.8) 8-1 (0.3) 7-7 (0.9) 3-8 (0.8)t 8-4 (0.3) 8.1 (0.4) 6-9 (0.8)
*p=0.05 and i-p=0034 versus 5-ASA and placebo at fourth week after TNB exposure.
loma, fibrosis and the depth of the lesion
(Table II).16 Histological assessment by light
microscopy was performed in a blinded fashion
on coded slides.
Eicosanoid radioimmunoassay
Eicosanoid concentrations in the dialysates
were measured by specific radioimmunoassays
for prostaglandin E2 (PGE2), thromboxane B2
(TXB2), and LTB4 The measurements were
made two weeks after sample collection, in the
laboratory of neurochemistry of the Centro
Superior de Investigaciones Cientificas (CSIC,
Barcelona, Spain).
Immediately after intracolonic dialysis was
performed, the dialysate samples obtained
were acidified at pH 3.15 and directly
processed through Sep-Pak C18 cartridges
(Water Chromatography Division, Millipore
Co, Milford, MA). After washing with 10 ml of
acid water (pH 3-15) and 10 ml of petroleum
ether, eicosanoids were finally eluted with 5 ml
of methyl formate and collected in propylene
tubes. Afterwards, samples were evaporated of
organic eluates to dryness, and stored at
-80°C until assay. The extraction efficiency of
the three eicosanoids, tested with tritiated
standards (Amersham International, UK), was
similar (over 90%/o) and highly reproducible
(intra-assay variation of 2-5%).17-19
All radioimmunoassay determinations were
carried out in duplicate using specific antisera,
being the detection sensitivity of 30-40 pg/ml.
Samples were resuspended in radioimmuno-
assay buffer and subjected to radioimmunoassay
quantification. The recoveries were determined
by scintillation counting.19 Antiserum for
PGE2 was obtained from ERIA Diagnostics
Pasteur (Marnes La Coquette, France). For
TXB2 and LTB4 determination, non-commer-
cial rabbit antisera were used. Cross reactivity
of PGE3 with the PGE2 antiserum was
<0-01%; LTB5 crossreacted with the LTB4
antiserum at 17/1%. The PGE2 and TXB2
antisera showed a cross reactivity for TXB2
and PGE2 of less than 0 01 and 0*1%, respec-
tively. Validation of radioimmunoassay results
were carried out using both the test of inhibi-
tion with anti-inflammatory drugs and the test
of parallelism,20 obtaining in both cases strong
correlations (r=0 901 and r=0.953, respec-
tively).
Statistical methods
Results are expressed as mean (SEM).
Significant differences between groups were
evaluated using one-way analysis of variance.
Duncan multiple range test was used to assess
where the differences occur. Kruskall-Wallis
one way analysis of variance by ranks and
Mann-Whitney U test were used for non-para-
metric variables. Statistical analysis was per-
formed using SPSS (SPSS Inc, Chicago, IL).
Results
Effects of treatment on macroscopic colonic
damage
As previously described, intracolonic admini-
stration of TNB/ethanol resulted in extensive
ulceration and transmural inflammation of the
distal colon with severe thickening of the bowel
wall and strictures. In addition, segmental
pericolonic accumulations of mesenteric fat
and fibrinous adhesions to the small bowel
were frequently seen.
The macroscopic damage score evaluated at
weeks 1 and 2 after the colonic injury was
similar in the three groups studied. Zileuton
treated rats, however, showed a significant
reduction in the macroscopic damage score
after four weeks of treatment compared with
5-ASA and placebo groups (3.85 (0.7) v 6.9
(0.8), and 6.1 (0.8), respectively; p=0.034).
All parameters measured by the score
improved in zileuton group at four weeks com-
pared with 5-ASA and placebo, mainly the
development of strictures (0.6 (0.4) v 1.9 (0.3)
and 1.4 (0-4), respectively; p=0.05) (Table
III).
In the control group, no macroscopic dam-
age was observed 48 hours after the induction
of the sham colitis.
10 r
8
6
4
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--- Placebo
Zileuton
_ ---- 5-ASA
1 Wk 2 Wk 4 Wk
Figure 1: Effects of intracolonic administration of zileuton
(50 mg/kg), 5-ASA (50 mg/kg) and placebo (vehicle)
from days 1 to 28 on histological score after TNB induction
of colitis (30 mg/50%/y). Each point represents the mean
(SEM) of at least seven rats. There were no differences
among the three groups studied.
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pigure 2: Rat colons at one, two, andfour weeks after
exposure to TNB (30 mg/50%O) (haematoxylin and eosin,
magnification X 140). (A) Atfirst week, extensive ukers
with necrosis ofmucosa and submucosa and infiltration with
polymorphonuclear leucocytes were observed. (B) At second
week, necrotic areas ofmucosa and submucosa were replaced
by exuberant granulation tissue. Mucosa adjacent to ulcers
showed important glandular distortion, globet cells depletion,
and cystically dilated cripts. (C) Four weeks after TNB
administration, ulcers were partially reepithelisated. A mild
chronic inflammatory infiltrate was evident in either mucosa
and submucosa. Fibrosis extended through the whole
thickness of the bowel wal from superficial mucosa to serosa.
Effects of treatment on histological score
There were no differences in the histological
score among the groups, at weeks 1, 2 and 4
(Fig 1). The characteristics of the lesions
observed were similar to those previously
described5 11 15 (Fig 2).
Effect of treatment on intracolonic eicosanoid
release
As shown in Figures 3, 4, and 5, TNB induc-
tion of colitis resulted in a significant increase
in intracolonic TXB2, PGE2, and LTB4 release
when compared with the sham colitis group.
These increased concentrations were main-
tained throughout the study period.
Administration of zileuton produced a
significant increase in the intracolonic release
of both TXB2 (p=0.05 at week 1 compared
with either placebo or 5-ASA) and PGE2
--- Placebo
Zileuton
---- 5-ASA
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Figure 3: Influence of intracolonic administration of
zileuton (50 mg/kg), 5-ASA (50 mg/kg), and placebo
(vehicle) from days 1 to 28 after TNB administration
(30 mg/50%O) on luminal TXB2 release. Each point
represents the mean (SEM) of at least seven rats. Shaded
area represents the 95% confidence interval of the mean
value obtainedfrom rats with sham colitis (intracolonic
administration of 0.9% saline instead of TNB). At each
time, TXB2 levels in rats with TNB colitis and sham colitis
differed significantly (p<005). *p=0 05 as compared
with placebo and 5-ASA.
(p=0 005 at week 2 compared with either
placebo or 5-ASA, and p=0.04 at week 4 com-
pared with placebo) (Figs 3 and 4). TXB2 and
PGE2 release did not differ between placebo
and 5-ASA groups. On the other hand, both
zileuton and 5-ASA administration resulted in
a 90°/O abolition of LTB4 release at day 3 after
induction of colitis compared with placebo
(Fig 5).
Effect of treatment on dietary intake, weight
changes, and mortality
There were no differences between the three
therapeutic groups with regard to dietary
intake and weight change during the study
period. However, dietary intake was lower in
the treatment groups than in healthy rats under
the same living conditions and this was accom-
panied by weight loss of 12-15% during the
first two weeks. Afterwards the growth rates
returned to normal. Mortality was 20% in the
three therapeutic groups: most deaths
occurred in the first two weeks. Causes of
death, assessed by laparotomy post mortem,
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Figure 4: Influence of intracolonic administration of
zileuton (50 mg/kg), 5-ASA (50 mg/kg), and placebo
(vehicle) from days 1 to 28 after TNB administration
(30 mg/5O%) on luminal PGE2 release. Each point
represents the mean (SEM)of at least seven rats. Shaded
area represents the 95% confidence interval of the mean
value obtainedfrom rats with sham colitis (intracolonic
administration of 0.9% saline instead of TNB). At each
time, PGE2 levels in rats with TNB colitis and sham colitis
differed significantly (p<0-05). *p= 0-005 versus both
placebo and 5-ASA groups; tp= 0 04 versus placebo.
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Figure 5: Influence of intracolonic administration of
zileuton (50 mg/kg), 5-ASA (50 mg/kg), and placebo
(vehicle) from days 1 to 28 after TNB administration
(30 mg/S5Oo) on luminal LTB4 release. Each point
represents the mean (SEM) of at least seven rats. The
shaded area represents the 95% confidence interval of the
mean value obtainedfrom rats with sham colitis
(intracolonic administration of 0.9% saline instead of
TNB). At each time, LTB4 levels in rats with TNB colitis
and sham colitis differed significantly (p<0 05). *p<0. 005
versus zileuton and 5-ASA.
were colonic occlusion (13 rats) and intestinal
perforation (5 rats).
Discussion
TNB colitis in the rat is the animal model of
IBD most extensively used over the past few
years. The patterns of cytokine and mediator
expression in this model parallel those seen in
human IBD.21 Therefore, although the mech-
anisms by which inflammation is induced may
be not ideal for studying the initial events of
human IBD, it does provide a good model for
gut injury, inflammation, and repair.
The evidence of an aetiopathogenic role of
leukotrienes in the inflammatory process of
experimental and human colitis has prompted
several studies using different leukotriene syn-
thesis inhibitors.6 8A11 22 23 These substances
resulted in a 50 to 90% inhibition of LTB4
synthesis. However, the administration of
these drugs when colitis has already been
induced did not improve the inflammatory
process.9 10 23 Conversely, the administration
of the drug before the induction of colitis (one
to three hours beforehand) was associated with
a reduction in the severity of the colonic
inflammation.6 9-11
In the present study, the intracolonic
administration of 50 mg/kg of zileuton after
colitis induction decreased the local peak
release ofLTB4 by 90%. As in previous studies
using other 5-lipoxygenase inhibitors, this was
not associated with an improvement in colonic
inflammation parameters during the first two
weeks. However, there was a significant reduc-
tion in the macroscopic colonic damage score
at four weeks (chronic phase of colitis), when
compared with placebo and 5-ASA, a finding
not previously documented as most studies
lasted only two weeks.
Although zileuton diminished the damage as
measured by the macroscopic score, we did not
observe any difference in the histological score
between the three groups during the study
period. This is probably because these scores
evaluate different aspects. Macroscopic score
measures the extension of the lesions both
longitudinally and in depth, whereas the
microscopic score evaluates inflammation in
specimens that are always taken from inflamed
areas independently of the extension and depth
of the inflammatory process.
Although 5-ASA administration in our study
promoted a potent inhibition of LTB4 peak
release similar to that observed after zileuton, it
did not ameliorate either the acute or chronic
colonic damage when compared with placebo.
This finding contrasts with previous reports.
Vilaseca et al 5 demonstrated a significant
reduction in macroscopic and histological
lesions after 21 days of treatment with intra-
colonic 5-ASA. However, the dose used in that
trial was nearly 15-fold higher than in our
study, and at least 1 0-fold higher than the dose
used in treating human IBD. On the other
hand, it has been shown that pretreating rats
with colonically administered 5-ASA resulted in
significantly less inflammation,69 whereas giv-
ing this treatment one day after TNB did not.9
In addition to the inhibition of LTB4 syn-
thesis after treatment, monitoring of eicosanoid
release allowed us to observe a maintained
increase in post-treatment PGE2 production
over the whole period of study. This was not
observed after either placebo or 5-ASA treat-
ment. Although less noticeable, there was also
a maintained increase in TXB2 release after
zileuton. These observations suggest that the
inhibition of 5-lipoxygenase leads to a shifting
of arachidonic acid to the cyclooxygenase
pathway. In the only previous study on the
effect of a 5-lipoxygenase inhibitor in TNB
induced colitis, in which eicosanoid produc-
tion was monitored over four weeks, a signifi-
cant increase in prostaglandin synthesis was
not observed.6 Nevertheless, in that study
6-keto PGF1, instead of PGE2 was measured
as an index of cyclooxygenase activity. It is
known that eicosanoid production is tissue
and cell specific. The major source of PGI2
(precursor of 6-keto PGFia) is the endothelial
cell, whereas PGE2 may be produced by many
cell types, even by epithelial cells.
For many years PGE2 was considered an
important mediator of the inflammatory
response in IBD.24-28 However, there is now
clear evidence refuting this view. In fact inhibi-
tion of PGE2 by non-steroidal anti-inflamma-
tory drugs exacerbated rather than improved
the severity of experimental colitis,1' and in
patients with IBD, the use of these drugs was
associated with disease relapse.29 30 Moreover,
exogenous prostaglandins have been shown to
reduce the severity of intestinal damage in a
number of experimental models of colitis.6 31-33
These observations suggest that prostaglandins
are not proinflammatory and that they even pro-
mote healing through a variety of actions. In
relation to this, a protective effect of these
agents on the proliferative zone ofthe mucosa,33
and an association between PGE2 synthesis and
the adherent surface colonic mucus secretion34
have been reported. On the other hand, PGE2
may exert many immunomodulatory changes in
neutrophils,35 T lymphocytes,36 natural killer
cells,37 and macrophages.38 Recent data also
suggest that prostaglandins are involved in the
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formation of extracelluar matrix components
and may decrease collagen synthesis after
inflammation.39 40
All these findings raise the possibility that
maintaining increased levels of PGE2 over at
least four weeks could be the main explanation
for the different disease outcomes after zileu-
ton and 5-ASA treatment, since the inhibition
of LTB4 synthesis was similar in both actively
treated groups of rats.
Thromboxanes have also been implicated in
the pathogenesis of experimental colitis. The
administration of two specific thromboxane
inhibitors significantly reduced the severity of
the chronic inflammatory lesions. The authors
suggested that this effect was due to increased
mucosal prostaglandin synthesis.5 The results
of our study support this suggestion, since
improvement in the intestinal damage was
observed after zileuton treatment despite
increased TXB2 synthesis.
In summary, this study suggests that chronic
intracolonic administration of zileuton, a selec-
tive 5-lipoxygenase inhibitor, may improve the
course of the disease, when compared with 5-
ASA and placebo. This effect may be related to
an increased and maintained production of
PGE2, together with the inhibition of the
synthesis of LTB4.
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